AMPE: AI 评分 48/100 — AI 分析 (4月 2026)

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing immunomodulatory therapies for osteoarthritis and COVID-19 related respiratory distress. Their pipeline includes treatments in various stages of clinical trials, targeting significant unmet needs in pain management and respiratory diseases.

Key Facts: AI Score: 48/100 Sector: Healthcare

公司概况

概要：

Ampio Pharmaceuticals, Inc. is a biopharmaceutical firm concentrating on immunomodulatory therapies, primarily targeting osteoarthritis pain with its AP-013 Phase III trial. The company also develops treatments for COVID-19-related respiratory conditions, including AP-017, AP-019, and AP-018, positioning it within the evolving landscape of pain management and viral disease therapeutics.

AMPE是做什么的？

Ampio Pharmaceuticals, Inc., headquartered in Englewood, Colorado, is a biopharmaceutical company dedicated to the development of immunomodulatory therapies. The company focuses on addressing unmet medical needs in areas such as pain management and respiratory diseases. Its lead product candidate, AP-013, is an intra-articular injection currently in Phase III clinical trials for the treatment of osteoarthritis of the knee. This therapy aims to provide pain relief and improve joint function for patients suffering from this debilitating condition. In addition to its osteoarthritis program, Ampio Pharmaceuticals is actively involved in developing treatments for COVID-19-related respiratory complications. The company's pipeline includes AP-017, an intravenous ampion treatment in Phase II clinical trials for adult COVID-19 patients requiring oxygen supplementation. Furthermore, AP-019, an inhaled ampion treatment, is also in Phase II clinical trials for adults with respiratory distress due to COVID-19. AP-018 is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. These programs reflect Ampio's commitment to addressing the ongoing challenges posed by the COVID-19 pandemic. Founded with the goal of developing innovative therapies, Ampio Pharmaceuticals continues to advance its research and development efforts to bring new treatment options to patients.

AMPE的投资论点是什么？

Ampio Pharmaceuticals presents a high-risk, high-reward investment profile, primarily driven by its clinical pipeline. The success of AP-013 in Phase III trials for osteoarthritis of the knee is a key value driver. Positive results and subsequent FDA approval could lead to significant revenue generation, addressing a large market with unmet needs. The company's COVID-19 programs, while earlier in development, offer additional upside potential, particularly if effective treatments for respiratory distress can be brought to market. However, the company's OTC listing and limited financial resources pose significant risks. The company's high beta of 7.17 indicates high volatility. Investment hinges on successful clinical trial outcomes and the ability to secure funding to advance its pipeline.

AMPE在哪个行业运营？

Ampio Pharmaceuticals operates within the biotechnology industry, a sector characterized by high innovation, regulatory scrutiny, and capital intensity. The company's focus on immunomodulatory therapies places it within a competitive landscape that includes both established pharmaceutical companies and emerging biotech firms. The osteoarthritis market is substantial, with a growing aging population driving demand for effective pain management solutions. The COVID-19 pandemic has also created a significant need for therapies targeting respiratory complications, presenting both opportunities and challenges for companies like Ampio. Competitors include companies developing similar therapies for osteoarthritis and respiratory diseases.

Biotechnology

Healthcare

AMPE有哪些增长机遇？

Successful Completion of AP-013 Phase III Trial: The successful completion of the Phase III clinical trial for AP-013 represents a significant growth opportunity for Ampio Pharmaceuticals. Positive results would pave the way for regulatory approval and commercialization, potentially capturing a substantial share of the osteoarthritis pain management market. The timeline for this opportunity is dependent on the trial's progress and regulatory review, with potential revenue generation starting within 2-3 years post-approval. The osteoarthritis market is estimated to be worth billions of dollars, offering substantial revenue potential.
Advancement of COVID-19 Pipeline: The advancement of Ampio's COVID-19 pipeline, including AP-017, AP-019 and AP-018, presents another growth opportunity. Successful clinical trials and regulatory approvals could position Ampio as a key player in the treatment of COVID-19-related respiratory complications. The timeline for this opportunity is dependent on the progress of clinical trials and regulatory review, with potential revenue generation starting within 1-2 years post-approval. The market for COVID-19 therapies remains significant, although evolving with the pandemic.
Partnerships and Collaborations: Forming strategic partnerships and collaborations with larger pharmaceutical companies could provide Ampio with access to additional funding, expertise, and resources to accelerate the development and commercialization of its pipeline. This could involve licensing agreements, joint ventures, or co-development partnerships. The timeline for this opportunity is variable, dependent on the negotiation and execution of agreements. Such partnerships could significantly enhance Ampio's growth prospects.
Expansion of Pipeline into New Indications: Ampio could explore expanding its pipeline into new indications beyond osteoarthritis and COVID-19. This could involve leveraging its immunomodulatory platform to develop therapies for other inflammatory or autoimmune diseases. The timeline for this opportunity is longer-term, requiring significant research and development efforts. Successful expansion into new indications could diversify Ampio's revenue streams and reduce its reliance on its current pipeline.
Geographic Expansion: Expanding its geographic reach beyond the United States could provide Ampio with access to new markets and patient populations. This could involve seeking regulatory approvals in other countries and establishing commercial operations in those regions. The timeline for this opportunity is dependent on regulatory requirements and market entry strategies. Geographic expansion could significantly increase Ampio's revenue potential.

AP-013 is in Phase III clinical trials for osteoarthritis of the knee, targeting a significant market for pain management.
AP-017 is in Phase II clinical trials for treating adult COVID-19 patients requiring oxygen supplementation, addressing a critical need during the pandemic.
AP-019 is in Phase II clinical trials for treating adults with respiratory distress due to COVID-19, expanding the company's focus on respiratory therapies.
AP-018 is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19.
The company has a market capitalization of $0.00B, reflecting its current stage of development and associated risks.

AMPE提供哪些产品和服务？

Develop immunomodulatory therapies.
Focus on treatments for osteoarthritis pain.
Develop treatments for COVID-19-related respiratory complications.
Conduct clinical trials to evaluate the safety and efficacy of its therapies.
Seek regulatory approvals for its products.
Commercialize approved therapies.

AMPE如何赚钱？

Develop and patent novel immunomodulatory therapies.
Conduct clinical trials to demonstrate efficacy and safety.
Seek regulatory approval from the FDA and other agencies.
Commercialize approved therapies through direct sales or partnerships.

Patients suffering from osteoarthritis of the knee.
Adult COVID-19 patients requiring oxygen supplementation.
Adults with respiratory distress due to COVID-19.
Healthcare providers who prescribe and administer Ampio's therapies.

Patented therapies provide exclusivity and protect market share.
Clinical trial data demonstrating efficacy and safety.
Established relationships with key opinion leaders and healthcare providers.

什么因素可能推动AMPE股价上涨？

Upcoming: AP-013 Phase III clinical trial results for osteoarthritis of the knee.
Upcoming: Regulatory submissions and potential approvals for AP-013.
Ongoing: Progress in clinical trials for AP-017, AP-019 and AP-018 for COVID-19-related respiratory complications.
Ongoing: Potential partnerships and collaborations with larger pharmaceutical companies.
Ongoing: Expansion of pipeline into new indications.

AMPE的主要风险是什么？

Potential: Clinical trial failures for AP-013 or other pipeline candidates.
Potential: Regulatory delays or rejections.
Ongoing: Competition from established pharmaceutical companies.
Ongoing: Inability to secure additional funding.
Potential: Liquidity risks associated with OTC trading.

AMPE的核心优势是什么？

Pipeline of immunomodulatory therapies.
Focus on unmet medical needs in osteoarthritis and COVID-19.
AP-013 in Phase III clinical trials for osteoarthritis.
Experienced management team.

AMPE的劣势是什么？

Limited financial resources.
High reliance on clinical trial outcomes.
OTC listing indicates higher risk.
Small number of employees.

AMPE有哪些机遇？

Successful completion of AP-013 Phase III trial.
Advancement of COVID-19 pipeline.
Partnerships and collaborations with larger pharmaceutical companies.
Expansion of pipeline into new indications.

AMPE面临哪些威胁？

Clinical trial failures.
Regulatory hurdles.
Competition from established pharmaceutical companies.
Inability to secure additional funding.

AMPE的竞争对手是谁？

Arani Biosciences, Inc. — Developing therapies for ophthalmic diseases. — (ARNI)
Better Therapeutics, Inc. — Developing prescription digital therapeutics. — (BTTX)
Baudax Bio, Inc. — Focuses on pain management solutions. — (BXRXQ)
Caladrius Biosciences, Inc. — Developing cell therapies for autoimmune and inflammatory diseases. — (CALA)
IV BioTherapeutics, Inc. — Developing cell-based therapies. — (IVBT)

Key Metrics

MoonshotScore: 48/100

Company Profile

CEO: Michael A. Martino
Headquarters: Englewood, US
Employees: 6
Founded: 2010

AI Insight

AI analysis pending for AMPE

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Ampio Pharmaceuticals, Inc. do?

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing immunomodulatory therapies for the treatment of pain from osteoarthritis and respiratory diseases related to COVID-19. Its primary focus is on advancing its pipeline of drug candidates through clinical trials, with the goal of obtaining regulatory approvals and commercializing these therapies to address unmet medical needs in these areas. The company's lead product candidate, AP-013, is in Phase III clinical trials for osteoarthritis of the knee.

What do analysts say about AMPE stock?

As of March 16, 2026, there is no readily available analyst consensus on AMPE stock, likely due to its OTC listing and small market capitalization. Key valuation metrics such as price-to-earnings ratio are not meaningful due to negative earnings. Growth considerations center on the successful completion of clinical trials and potential regulatory approvals for its pipeline candidates. Investors should conduct their own thorough research and consider the risks associated with investing in a small, OTC-listed biopharmaceutical company.

What are the main risks for AMPE?

The main risks for Ampio Pharmaceuticals include clinical trial failures, regulatory hurdles, competition from established pharmaceutical companies, and the need to secure additional funding to support its research and development activities. As an OTC-listed company, AMPE also faces liquidity risks and potential volatility due to lower trading volumes. The success of the company hinges on the positive outcomes of its clinical trials and the ability to navigate the complex regulatory landscape.